IBM Watson Health has formed a medical imaging collaborative with more than 15 leading healthcare organizations. The goal: To take on some of the most deadly diseases. The collaborative, which includes health systems, academic medical centers, ambulatory radiology providers and imaging technology companies, aims to help doctors address breast, lung, and other cancers; diabetes; eye health; brain disease; and heart disease and related conditions, such as stroke. Watson will mine insights from what IBM calls previously invisible unstructured imaging data and combine it with a broad variety of data from other sources, such as data from electronic health records, radiology and pathology reports, lab results, doctors' progress notes, medical journals, clinical care guidelines and published outcomes studies. As the work of the collaborative evolves, Watson's rationale and insights will evolve, informed by the latest combined thinking of the participating organizations.
Predicated on the increasing abundance of electronic health records, we investigate the problem of inferring individualized treatment effects using observational data. Stemming from the potential outcomes model, we propose a novel multi-task learning framework in which factual and counterfactual outcomes are modeled as the outputs of a function in a vector-valued reproducing kernel Hilbert space (vvRKHS). We develop a nonparametric Bayesian method for learning the treatment effects using a multi-task Gaussian process (GP) with a linear coregionalization kernel as a prior over the vvRKHS. The Bayesian approach allows us to compute individualized measures of confidence in our estimates via pointwise credible intervals, which are crucial for realizing the full potential of precision medicine. The impact of selection bias is alleviated via a risk-based empirical Bayes method for adapting the multi-task GP prior, which jointly minimizes the empirical error in factual outcomes and the uncertainty in (unobserved) counterfactual outcomes. We conduct experiments on observational datasets for an interventional social program applied to premature infants, and a left ventricular assist device applied to cardiac patients wait-listed for a heart transplant. In both experiments, we show that our method significantly outperforms the state-of-the-art.
One of the ways AI is and will continue t be helpful in the field of healthcare is allowing medical professionals the ability to create treatment plans as well as discovering the best suited methods for helping their patients; instead of having to battle the tread-wheel of bureaucracy, nurses and physicians can focus on doing their actual jobs. Since we are in the age of big data, patient information is becoming valuable as tech giants, such as IBM and Google, are becoming more involved in acquiring this information; therefore, companies are using AI in the field known as patient data mining in a variety of ways. The AI research branch of the company recently launched a project known as Google Deepmind Health which focuses on mining medical records with the goal of providing faster and better health services; the project can go through hundreds of thousands of medical data within minutes. Also, Google's life sciences are working on a data-collecting initiative that aims to apply some of the same algorithms used to power Goggle's search button to analyze what it is that makes a person healthy. Included in this is experimenting with technologies that monitor diseases such as a digital contact lens that might detect levels of blood sugar.
Tandy J. Warnow Department of Computer Science University of Arizona Tucson AZ USA email: tandy cs, arizona, edu Abstract In an earlier paper, we described a new method for phylogenetic tree reconstruction called the Disk Covering Method, or DCM. This is a general method which can be used with an)' existing phylogenetic method in order to improve its performance, lCre showed analytically and experimentally that when DCM is used in conjunction with polynomial time distance-based methods, it improves the accuracy of the trees reconstructed. In this paper, we discuss a variant on DCM, that we call DCM2. DCM2 is designed to be used with phylogenetic methods whose objective is the solution of NPhard optimization problems. We also motivate the need for solutions to NPhard optimization problems by showing that on some very large and important datasets, the most popular (and presumably best performing) polynomial time distance methods have poor accuracy. Introduction 118 HUSON The accurate recovery of the phylogenetic branching order from molecular sequence data is fundamental to many problems in biology. Multiple sequence alignment, gene function prediction, protein structure, and drug design all depend on phylogenetic inference. Although many methods exist for the inference of phylogenetic trees, biologists who specialize in systematics typically compute Maximum Parsimony (MP) or Maximum Likelihood (ML) trees because they are thought to be the best predictors of accurate branching order. Unfortunately, MP and ML optimization problems are NPhard, and typical heuristics use hill-climbing techniques to search through an exponentially large space. When large numbers of taxa are involved, the computational cost of MP and ML methods is so great that it may take years of computation for a local minimum to be obtained on a single dataset (Chase et al. 1993; Rice, Donoghue, & Olmstead 1997). It is because of this computational cost that many biologists resort to distance-based calculations, such as Neighbor-Joining (NJ) (Saitou & Nei 1987), even though these may poor accuracy when the diameter of the tree is large (Huson et al. 1998). As DNA sequencing methods advance, large, divergent, biological datasets are becoming commonplace. For example, the February, 1999 issue of Molecular Biology and Evolution contained five distinct datascts of more than 50 taxa, and two others that had been pruned below that.
Health care executives from IBM Watson and Athenahealth athn debated that question onstage at Fortune's inaugural Brainstorm Health conference Tuesday. In addition to partnering with Celgene celg to better track negative drug side effects, IBM ibm is applying its cognitive computing AI technology to recommend cancer treatment in rural areas in the U.S., India, and China, where there is a dearth of oncologists, said Deborah DiSanzo, general manager for IBM Watson Health. For example, IBM Watson could read a patient's electronic medical record, analyze imagery of the cancer, and even look at gene sequencing of the tumor to figure out the optimal treatment plan for a particular person, she said. "That is the promise of AI--not that we are going to replace people, not that we're going to replace doctors, but that we really augment the intelligence and help," DiSanzo said. Athenahealth CEO Jonathan Bush, however, disagreed.